Effects of Alendronate on Reproductive Endocrine Hormone, Immunocytokines and Bone Metabolism in Postmenopausal Osteoporosis Patients
This paper investigates the effects of alendronate on reproductive endocrine hormones, immune cytokines and bone metabolism in postmenopausal osteoporosis patients.From January 2018 to March 2019, 180 female osteoporotic patients aged 55 to 70 years who were admitted to our hospital from January 2016 to March 2017 were randomized into calcium and sodium alendronate groups using a random number table method. Each group of patients measured endocrine hormones (including follicle-stimulating hormone, estradiol, luteinizing hormone, testosterone), immune cytokines (including IL-6, TNF-a), and bone metabolism before and 24 weeks after treatment. Serum levels of indicators (calcitonin, parathyroid hormone, osteocalcin), etc. There was no significant difference in endocrine hormones, immune cytokines, and bone metabolic indexes before treatment (P>0.05);Alendronate group: After treatment, the levels of FSH, estradiol, osteocalcin, parathyroid hormone, and calcitonin in the reproductive endocrine hormones were significantly higher than before treatment (P<0.05). After treatment, IL-6, There was no significant change in TNF-a levels;In the calcium group, the levels of follicle stimulating hormone, estradiol, osteocalcin, parathyroid hormone, and calcitonin in the reproductive endocrine hormones decreased after treatment, but the levels were decreased. IL-6 and TNF-a levels after treatment rise.Alendronate can effectively increase the level of reproductive endocrine hormones and bone metabolic hormones in patients with postmenopausal osteoporosis, and at the same time it has a certain inhibitory effect on the increase of immune cytokines in patients with osteoporosis.